Entera Bio
Entera Bio Ltd. is a leader in the development of orally delivered peptides and therapeutic proteins, focusing on significant unmet medical needs. Its mission is to transform the standard of care with simple, oral mini-tablet peptide replacement therapies. The company's advanced product candidates include EB613 for osteoporosis and EB612 for hypoparathyroidism, both in clinical development. Entera also licenses its technology to biopharmaceutical companies and has collaborations with major industry players like Amgen.
Industries
Nr. of Employees
small (1-50)
Patents
Products
Oral parathyroid hormone (PTH 1-34) mini-tablet for osteoporosis
An oral, once-daily mini-tablet formulation of PTH (1-34) developed to produce systemic exposure comparable to injectable anabolic therapy and to increase bone mineral density in postmenopausal osteoporosis.
Oral PTH formulation for hypoparathyroidism
Orally dosed PTH formulation developed for replacement therapy in hypoparathyroidism, supported by Phase 2 clinical data and peer-reviewed publication.
Oral GLP-2 / oxyntomodulin / GLP-1 peptide tablet candidates
Orally formulated peptide tablet candidates directed at short bowel syndrome, obesity and metabolic disorders evaluated for PK/PD and systemic exposure.
Oral Oxyntomodulin
An oral dual agonist GLP-1/glucagon peptide candidate combining OPKO's proprietary long-acting oxyntomodulin analog (OPK-88006) and Entera's N-Tab platform as a potential once-daily treatment for obesity and metabolic disorders.
Oral Oxyntomodulin Peptide Tablet
Dual targeted GLP1/glucagon peptide in tablet form for the treatment of obesity.
N-Tab Platform
A proprietary oral peptide delivery platform designed to convert diverse peptide drugs into oral formulations in tablet form by protecting against proteolytic degradation and enhancing permeability.
Oral parathyroid hormone (PTH 1-34) mini-tablet for osteoporosis
An oral, once-daily mini-tablet formulation of PTH (1-34) developed to produce systemic exposure comparable to injectable anabolic therapy and to increase bone mineral density in postmenopausal osteoporosis.
Oral PTH formulation for hypoparathyroidism
Orally dosed PTH formulation developed for replacement therapy in hypoparathyroidism, supported by Phase 2 clinical data and peer-reviewed publication.
Oral GLP-2 / oxyntomodulin / GLP-1 peptide tablet candidates
Orally formulated peptide tablet candidates directed at short bowel syndrome, obesity and metabolic disorders evaluated for PK/PD and systemic exposure.
Oral Oxyntomodulin
An oral dual agonist GLP-1/glucagon peptide candidate combining OPKO's proprietary long-acting oxyntomodulin analog (OPK-88006) and Entera's N-Tab platform as a potential once-daily treatment for obesity and metabolic disorders.
Oral Oxyntomodulin Peptide Tablet
Dual targeted GLP1/glucagon peptide in tablet form for the treatment of obesity.
N-Tab Platform
A proprietary oral peptide delivery platform designed to convert diverse peptide drugs into oral formulations in tablet form by protecting against proteolytic degradation and enhancing permeability.
Services
Licensing of oral formulation technology and collaborative formulation development for third-party peptide and protein compounds.
Protocol design, regulatory briefing package preparation, and operational support for Phase 2/3 clinical studies of orally delivered peptide therapeutics.
Licensing of oral formulation technology and collaborative formulation development for third-party peptide and protein compounds.
Protocol design, regulatory briefing package preparation, and operational support for Phase 2/3 clinical studies of orally delivered peptide therapeutics.
Expertise Areas
- Oral biologic delivery
- Peptide formulation development
- Clinical trial design for registrational studies
- Pharmacokinetics and PK/PD analysis
Key Technologies
- Oral absorption enhancement (chemical permeation enhancers)
- Protease inhibition for GI protection
- Mini-tablet oral dosage forms
- Population PK modeling
News & Updates
Entera Bio announced that the FDA has accepted a Type D meeting protocol review to confirm the design of its Phase 3 study for EB613, the first oral osteoanabolic treatment for postmenopausal osteoporosis.
Research published in the International Journal of Pharmaceutics describes Entera's oral delivery technology, which underpins its lead product EB613 and other molecules in development.
Entera Bio announced that the FDA has accepted a Type D meeting protocol review to confirm the design of its Phase 3 study for EB613, the first oral osteoanabolic treatment for postmenopausal osteoporosis.
Research published in the International Journal of Pharmaceutics describes Entera's oral delivery technology, which underpins its lead product EB613 and other molecules in development.